PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Dover, DE.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of PhaseBio Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. PhaseBio Pharmaceuticals Inc market cap is $0.00.
What is the 52-week high for PhaseBio Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. PhaseBio Pharmaceuticals Inc 52 week high is $0.0369 as of May 06, 2024.
What is the 52-week low for PhaseBio Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. PhaseBio Pharmaceuticals Inc 52 week low is $0.00 as of May 06, 2024.
What is the 50-day moving average of PhaseBio Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. PhaseBio Pharmaceuticals Inc 50-day moving average is $0.00.